Disagree
Home Substances
Toremifene Citrate

Toremifene Citrate

A-Z
Search for:
Substance Overview and History

Toremifene, a selective estrogen receptor modulator (SERM), synthesized in 1981 and introduced commercially by 1990, treats metastatic breast cancer in postmenopausal women. By blocking receptors in breast tissue it is limiting tumor growth. Available mainly as toremifene citrate, it has been compared to tamoxifen in trials, showing equivalent results. Studies on animals suggests its capability to lower tumor development in hormone sensitive tissues like mammary glands.

References:

IARC Working Group on the Evaluation of Carcinogenic Risks to Humans (1996). Some Pharmaceutical Drugs. Lyon (FR): International Agency for Research on Cancer. (IARC Monographs on the Evaluation of Carcinogenic Risks to Humans.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For more details consult with your doctor or healthcare professional.

FAQ
What is Toremifene (SERM) used for?
Toremifene Citrate is primarily used to treat metastatic breast cancer in postmenopausal women.
References:

IARC Working Group on the Evaluation of Carcinogenic Risks to Humans (1996). Some Pharmaceutical Drugs. Lyon (FR): International Agency for Research on Cancer. (IARC Monographs on the Evaluation of Carcinogenic Risks to Humans.

How does Toremifene exactly work?
Toremifene blocks estrogen receptors in breast tissue, reducing the growth of estrogen dependent tumors.
References:

IARC Working Group on the Evaluation of Carcinogenic Risks to Humans (1996). Some Pharmaceutical Drugs. Lyon (FR): International Agency for Research on Cancer. (IARC Monographs on the Evaluation of Carcinogenic Risks to Humans.

Is Toremifene similar to tamoxifen?
Yes ,Toremifene is similar to tamoxifen, with both drugs showing comparable efficiency in clinical trials.
References:

IARC Working Group on the Evaluation of Carcinogenic Risks to Humans (1996). Some Pharmaceutical Drugs. Lyon (FR): International Agency for Research on Cancer. (IARC Monographs on the Evaluation of Carcinogenic Risks to Humans.